tracken
Roivant Sciences Aktie News
Neutral
Seeking Alpha
●
19 Tage alt
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I cover U.S. biotech at Bernstein.
Neutral
Seeking Alpha
●
19 Tage alt
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bank of America Global Healthcare Conference 2025 September 24, 2025 5:45 AM EDT Company Participants Matthew Gline - CEO & Director Conference Call Participants Jason Gerberry - BofA Securities, Research Division Presentation Jason Gerberry BofA Securities, Research Division We're at time.
Neutral
Seeking Alpha
●
20 Tage alt
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q1 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Conference Call Participants Allison Bratzel - Piper Sandler Brian Cheng - JPMorgan Dave Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Louise Chen - Cantor Yatin Suneja - Guggenh...
Neutral
Seeking Alpha
●
26 Tage alt
Roivant Sciences Ltd. - Special Call Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Benjamin Zimmer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yaron Werber - TD Cowen, Res...
Positiv
The Motley Fool
●
26 Tage alt
Shares of Roivant Sciences (ROIV 12.14%) are soaring 11.4% higher as of 11:19 a.m. ET on Wednesday.
Positiv
Investors Business Daily
●
26 Tage alt
Shares of Roivant Sciences extended their breakout Wednesday, stoked by promising test results in a difficult-to-treat autoimmune disease.
Positiv
Reuters
●
26 Tage alt
Roivant and partner Priovant Therapeutics said on Wednesday that their experimental drug for a rare disease affecting both skin and muscle health has shown promising results in a late-stage clinical trial.
Neutral
GlobeNewsWire
●
26 Tage alt
BASEL, Switzerland and LONDON and NEW YORK and DURHAM, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 3 VALOR study evaluating brepocitinib in dermatomyositis (DM).
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
